IQLT
Quality FactoriShares MSCI Intl Quality Factor ETF
iShares · Tracks MSCI World ex USA Sector Neutral Quality Index · Inception Jan 13, 2015
Composite score
Based on a 0.30% expense ratio.
Based on $13.64B in net assets.
Top-10 holdings represent 24.9% of net assets.
Quality Factor base · ETF wrapper · 2.40% TTM yield.
The composite is a weighted average of the four core sub-scores above (cost, tax efficiency, liquidity, concentration). Missing sub-scores fall back to the per-category median when the category has at least 50% data coverage, so funds without (e.g.) parsed N-PORT holdings aren't accidentally boosted by renormalization. Tracking quality is shown where computable but isn't currently part of the composite weighting. See methodology for formulas, the tracking-quality partial-coverage rationale, and the dimensions we deliberately don't score (methodology v0.5.1).
Use IQLT in our tools
Tool · Cost
Compare IQLT's fee against another fund
Compounds the 0.30% expense ratio against a peer over decades.
Tool · Overlap
Compare IQLT's holdings with peers
Pairwise holdings heatmap, pre-loaded with similar Quality Factor funds.
Tool · TLH
Find a tax-loss harvesting partner for IQLT
Ranks every catalog fund by holdings overlap, flags wash-sale risk.
Tool · Placement
Where should this fund live across your accounts?
Asset-location optimizer — places each fund in taxable / tax-deferred / Roth.
Top holdings
| # | Holding | Weight |
|---|---|---|
| 1 | ASML Holding N.V. | 6.04% |
| 2 | SHELL PLC | 2.55% |
| 3 | Allianz SE | 2.49% |
| 4 | Novartis AG | 2.25% |
| 5 | ABB Ltd | 2.21% |
| 6 | Roche Holding AG | 2.17% |
| 7 | ASTRAZENECA PLC | 2.02% |
| 8 | Nestle S.A. | 1.99% |
| 9 | Zurich Insurance Group AG | 1.61% |
| 10 | Tokio Marine Holdings, Inc. | 1.55% |
Compare IQLT with another fund
Or skim the closest-overlap funds below.
Similar ETFs by holdings overlap
Open IQLT at a brokerage
Affiliate links — opening an account through these earns PlainIndex a one-time referral. Scoring is computed before any affiliate consideration; see our methodology and funding disclosure.